Literature DB >> 15732000

Merging models of hepatitis C virus pathogenesis.

Hans L Tillmann1, Michael P Manns, K Lenhard Rudolph.   

Abstract

Chronic hepatitis C virus (HCV) infection is one of the major causes for development of liver cirrhosis and end-stage liver disease. This article reviews two contrasting models of HCV pathogenesis, discusses the merits of each, and presents a rationale for combining the two models into one. Any successful model of HCV pathogenesis must explain how the characteristic features of cirrhosis and end-stage liver disease arise. These features include the loss of hepatocyte function (low serum albumin and reduced clotting ability); the presence of regenerative nodules; and the deposition of excessive extracellular matrix material, especially collagen (fibrosis), which is associated with the transformation of the liver sinusoids to capillary-like structures leading to portal hypertension. A successful model should explain several observations about the rate of disease progression. HCV is characterized by slow progression of fibrogenesis and, importantly, cirrhosis seems to develop only after a long latency (and only in a subset of patients). Among the prognostic factors of disease progression, the age at infection with the HCV virus and the presence of fibrosis appear to be highly relevant in predicting the development of progressive fibrosis. Traditional models of HCV pathogenesis propose that fibrogenesis is the predominant process. Fibrogenesis is induced by activation of fibrogenic cells, such as stellate cells, which results in excessive collagen deposition. By altering the normal architecture and vasculature, the collagen bands finally lead to cirrhosis and loss of organ function. Activation of stellate cells is induced by inflammation, cytokine signaling, and possibly by hepatocyte apoptosis. The telomere model of HCV pathogenesis suggests that hepatocyte damage plays an essential role in the development of cirrhosis. According to this model, hepatocyte damage leads to increased cell turnover, and to the accelerated shortening of hepatocyte telomeres. Critical telomere shortening leads to hepatocyte senescence, loss of hepatocyte function, exhaustion of hepatocellular regeneration, and to a greatly enhanced fibrotic response to injury. This review summarizes both models and presents evidence that these models are not mutually exclusive but rather can be merged into a comprehensive pathogenesis model that outlines the pathway of HCV-induced cirrhosis.

Entities:  

Mesh:

Year:  2005        PMID: 15732000     DOI: 10.1055/s-2005-864784

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  6 in total

Review 1.  Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease.

Authors:  A-J Demetris; John-G Lunz; Susan Specht; Isao Nozaki
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

2.  The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals.

Authors:  Matthew S Freiberg; Debbie M Cheng; Kevin L Kraemer; Richard Saitz; Lewis H Kuller; Jeffrey H Samet
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

3.  Modulations of cell cycle checkpoints during HCV associated disease.

Authors:  Saira Sarfraz; Saeed Hamid; Syed Ali; Wasim Jafri; Anwar A Siddiqui
Journal:  BMC Infect Dis       Date:  2009-08-10       Impact factor: 3.090

4.  Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies.

Authors:  Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mohamed Hassan
Journal:  World J Hepatol       Date:  2012-12-27

Review 5.  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.

Authors:  Scott L Friedman
Journal:  Physiol Rev       Date:  2008-01       Impact factor: 37.312

6.  Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes.

Authors:  Joel M O'Bryan; James A Potts; Herbert L Bonkovsky; Anuja Mathew; Alan L Rothman
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.